Par-Endo $8bn merger makes Mylan look undervalued
This article was originally published in Scrip
Executive Summary
In a deal that proves just what can be done when all shareholders can be consulted in a single elevator journey, Endo International and privately owned Par Pharmaceutical have put together a $8.05bn merger to create the fifth largest independent company in the generics pharmaceutical space. And the deal makes Teva's bid for Mylan look somewhat underpowered.
You may also be interested in...
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Stock Scan April 2018: Pharma's Fizz Falls Flat
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.